Glycostem Clinical Data Recap

January 2018 - In August of 2017, Clinical Cancer Research published a report on the positive outcome of Glycostem’s NK-killer cells phase I clinical trial, which was carried out at Radboud University Center in the Netherlands.

Lupus Ventures Takes Stake in Glycostem

December 2017 - Netherlands-based Lupus Ventures has invested €3 million in Glycostem, furthering the company’s expansion and ongoing technological development. Glycostem will channel this funding primarily to production optimisation and automation.